Telix Pharmaceuticals Ltd (TLX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Telix Pharmaceuticals Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Telix Pharmaceuticals Ltd (TLX) has returned 27.77% so far this year and -42.90% over the past 12 months.

Based on dividend-adjusted daily data since Nov 14, 2024, TLX's average daily return is -0.07%, while the average monthly return is -1.60%.

Historically, 35% of months were positive and 65% were negative. The best month was Mar 2026 with a return of +32.0%, while the worst month was Aug 2025 at -29.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.

On a daily basis, TLX closed higher 46% of trading days. The best single day was Feb 20, 2026 with a return of +14.6%, while the worst single day was Aug 28, 2025 at -16.1%.

Telix Pharmaceuticals Ltd has an annualized alpha of -22.01%, beta of 0.94, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since November 15, 2024.

• This stock participated in 88.32% of S&P 500 Index downside but only -85.27% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TLX ranks 16 for risk / return — in the bottom 16% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Telix Pharmaceuticals Ltd (TLX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Telix Pharmaceuticals Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Telix Pharmaceuticals Ltd was 69.37%, occurring on Feb 18, 2026. The portfolio has not yet recovered.

The current Telix Pharmaceuticals Ltd drawdown is 54.28%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Telix Pharmaceuticals Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Telix Pharmaceuticals Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.